Tendonitis Treatment Market (By Treatment: Therapy, Surgery; By Condition: Tennis Elbow, Golfer’s Elbow) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2023-2032

The global tendonitis treatment market was valued at USD 207.14 billion in 2022 and it is predicted to surpass around USD 300.20 billion by 2032 with a CAGR of 3.78% from 2023 to 2032.

Tendonitis Treatment Market Size 2023 to 2032

Key Pointers

  • In 2022, the therapy segment dominated the global industry and accounted for the largest share of more than 70.04% of the overall revenue.
  • In 2022, the Achilles tendonitis segment dominated the global industry and accounted for the largest share of more than 48.23% of the total revenue.
  • In 2022, North America dominated the global industry and accounted for the largest share of 43.58% of the overall revenue.
Report Coverage Details
Market Size in 2022 USD 207.14 billion
Revenue Forecast by 2032 USD 300.20 billion
Growth rate from 2023 to 2032 CAGR of 3.78%
Base Year 2022
Forecast Period 2023 to 2032
Regions Covered North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Covered Merck and Co. Inc.; Bayer AG; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Abbott; Pfizer; GlaxoSmithKline PLC; Almatica Pharma, Inc.

 

A growing aging population and sports & occupational work injuries & sudden injuries caused due to trauma or physical work are some of the factors that cause tendonitis, thereby contributing to the industry growth. Adolescents are becoming susceptible to arm-, wrist-, and hand-related injuries owing to the increasing usage of electronic devices, thereby, making them more prone to developing tendonitis. The growing prevalence of bone disorders, osteoarthritis, rheumatoid arthritis, and osteoporosis makes the geriatric population group susceptible to tendonitis.

Annually, over 70,000 U.S. individuals suffering from tendonitis miss their work, as per the Bureau of Labor Statistics. As per the WHO estimates in 2021, approximately 1.71 billion individuals globally are affected by musculoskeletal conditions and are prone to tendonitis. The increasing incidence of sports-related injuries due to the increased sports activities is contributing to the market growth. The adoption of healthy habits is increasing with people across the world taking up at least some physical activity regularly, this is anticipated to increase the incidence of sports injuries thereby contributing to the industry growth. Sports injuries make up 12% of the total injuries that are reported at hospitals in the U.S., most of which are tendon-related injuries.

According to a study published by sports medicine professors from Duke University and the University of Virginia, approximately 40 to 50% of competitive runners have suffered from Achilles tendinopathy. The growing incidence of tendonitis in the general population, which accounts for 5 to 10 cases per 100,000 people is attributed to an increase in the market demand during the forecast period. Various treatment options, such as OTC drugs, surgeries, and physical therapy have increased the number of individuals undergoing treatments, which will encourage the industry's growth. Physical therapy is one of the first lines of treatment for people with chronic tendon conditions as it helps in eccentric strengthening and is effective to treat chronic tendon conditions.

According to the international journal of physiotherapy, physical therapy is efficient to treat lower limb and upper limb tendinopathies, and these factors are attributed to an increase in the demand for the market during the forecast period. Tendons are highly aligned connective tissues that help transmit force from muscles to bones, hence these tissues are at a higher risk to get injured; over 32 million tendon-related injuries are reported every year, and tendinopathies are 50% of the injuries reported in sports players, and athletes. Sudden injuries, prolonged inactivity, and treatment-associated side effects are attributed to drive the industry during the forecast period.

Tendonitis Treatment Market Segmentations:

By Treatment 

  • Therapy
    • Hot and Cold Therapy
    • Physical Therapy
    • Shockwave Therapy
  • Surgery

By Condition

  • Tennis Elbow
  • Golfer’s Elbow
  • Pitcher’s Elbow
  • Jumper’s Knee
  • Swimmer’s Shoulder
  • Achilles Tendonitis

Frequently Asked Questions

The global tendonitis treatment market size was reached at USD 207.14 billion in 2022 and it is projected to hit around USD 300.20 billion by 2032.

The global tendonitis treatment market is growing at a compound annual growth rate (CAGR) of 3.78% from 2023 to 2032.

The North America region has accounted for the largest tendonitis treatment market share in 2022.

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Tendonitis Treatment Market 

5.1. COVID-19 Landscape: Tendonitis Treatment Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Tendonitis Treatment Market, By Treatment

8.1. Tendonitis Treatment Market, by Treatment, 2023-2032

8.1.1. Therapy

8.1.1.1. Market Revenue and Forecast (2019-2032)

8.1.2. Surgery

8.1.2.1. Market Revenue and Forecast (2019-2032)

Chapter 9. Global Tendonitis Treatment Market, By Condition

9.1. Tendonitis Treatment Market, by Condition, 2023-2032

9.1.1. Tennis Elbow

9.1.1.1. Market Revenue and Forecast (2019-2032)

9.1.2. Golfer’s Elbow

9.1.2.1. Market Revenue and Forecast (2019-2032)

9.1.3. Pitcher’s Elbow

9.1.3.1. Market Revenue and Forecast (2019-2032)

9.1.4. Jumper’s Knee

9.1.4.1. Market Revenue and Forecast (2019-2032)

9.1.5. Swimmer’s Shoulder

9.1.5.1. Market Revenue and Forecast (2019-2032)

9.1.6. Achilles Tendonitis

9.1.6.1. Market Revenue and Forecast (2019-2032)

Chapter 10. Global Tendonitis Treatment Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Treatment (2019-2032)

10.1.2. Market Revenue and Forecast, by Condition (2019-2032)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Treatment (2019-2032)

10.1.3.2. Market Revenue and Forecast, by Condition (2019-2032)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Treatment (2019-2032)

10.1.4.2. Market Revenue and Forecast, by Condition (2019-2032)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Treatment (2019-2032)

10.2.2. Market Revenue and Forecast, by Condition (2019-2032)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Treatment (2019-2032)

10.2.3.2. Market Revenue and Forecast, by Condition (2019-2032)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Treatment (2019-2032)

10.2.4.2. Market Revenue and Forecast, by Condition (2019-2032)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Treatment (2019-2032)

10.2.5.2. Market Revenue and Forecast, by Condition (2019-2032)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Treatment (2019-2032)

10.2.6.2. Market Revenue and Forecast, by Condition (2019-2032)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Treatment (2019-2032)

10.3.2. Market Revenue and Forecast, by Condition (2019-2032)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Treatment (2019-2032)

10.3.3.2. Market Revenue and Forecast, by Condition (2019-2032)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Treatment (2019-2032)

10.3.4.2. Market Revenue and Forecast, by Condition (2019-2032)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Treatment (2019-2032)

10.3.5.2. Market Revenue and Forecast, by Condition (2019-2032)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Treatment (2019-2032)

10.3.6.2. Market Revenue and Forecast, by Condition (2019-2032)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Treatment (2019-2032)

10.4.2. Market Revenue and Forecast, by Condition (2019-2032)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Treatment (2019-2032)

10.4.3.2. Market Revenue and Forecast, by Condition (2019-2032)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Treatment (2019-2032)

10.4.4.2. Market Revenue and Forecast, by Condition (2019-2032)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Treatment (2019-2032)

10.4.5.2. Market Revenue and Forecast, by Condition (2019-2032)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Treatment (2019-2032)

10.4.6.2. Market Revenue and Forecast, by Condition (2019-2032)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Treatment (2019-2032)

10.5.2. Market Revenue and Forecast, by Condition (2019-2032)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Treatment (2019-2032)

10.5.3.2. Market Revenue and Forecast, by Condition (2019-2032)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Treatment (2019-2032)

10.5.4.2. Market Revenue and Forecast, by Condition (2019-2032)

Chapter 11. Company Profiles

11.1. Merck and Co. Inc.

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Bayer AG

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. AstraZeneca

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Boehringer Ingelheim Pharmaceuticals, Inc.

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. LTE Scientific

11.5. Abbott

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Pfizer

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. GlaxoSmithKline PLC

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Almatica Pharma, Inc.

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers